Cellebrite DI (CLBT) Accumulated Expenses (2020 - 2025)

Cellebrite DI's Accumulated Expenses history runs 6 years deep, the most recent figure standing at $71.2 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 12.5% year-over-year to $71.2 million in Q4 2025; TTM through Dec 2025 was $71.2 million, a 12.5% increase from a year earlier, with the FY2025 full-year figure at $71.2 million, up 12.5% from the prior year.
• Accumulated Expenses rose to $71.2 million in Q4 2025 per CLBT's latest filing, from $62.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $71.2 million in Q4 2025 and bottomed at $35.6 million in Q2 2023.
• The 5-year median for Accumulated Expenses is $48.4 million (2022), against an average of $50.3 million.
• Across the five-year window, Accumulated Expenses declined 24.94% in 2023 and jumped 60.84% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $54.0 million in 2021, then retreated by 15.9% to $45.5 million in 2022, then retreated by 1.34% to $44.8 million in 2023, then jumped by 41.22% to $63.3 million in 2024, then climbed by 12.5% to $71.2 million in 2025.
• Per Business Quant, the three latest CLBT Accumulated Expenses figures stand at $71.2 million (Q4 2025), $62.5 million (Q3 2025), and $68.0 million (Q2 2025).